当前位置: 首页 >> 检索结果
4106. Hyperthyroidism.
Thyrotoxicosis is a general term for excess circulating and tissue thyroid hormone levels, whereas hyperthyroidism specifically denotes disorders involving a hyperactive thyroid gland (Graves disease, toxic multinodular goiter, toxic adenoma). Diagnosis and determination of the cause rely on clinical evaluation, laboratory tests, and imaging studies. Hyperthyroidism is treated with antithyroid drugs, radioactive iodine ablation, or thyroidectomy. Other types of thyrotoxicosis are monitored and treated with β-blockers to control symptoms given that most of these conditions resolve spontaneously.
4107. Should You Treat This Acutely Ill Medical Inpatient With Venous Thromboembolism Chemoprophylaxis?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
作者: Zahir Kanjee.;Kenneth A Bauer.;Anthony C Breu.;Risa Burns.
来源: Ann Intern Med. 2020年172卷7期484-491页
Venous thromboembolism (VTE), which includes both deep venous thrombosis and pulmonary embolism, is a common and potentially fatal condition. Medical inpatients are at high risk for VTE because of immobility as well as acute and chronic illness. Several randomized trials demonstrated that chemoprophylaxis, or low-dose anticoagulation, prevents VTE in selected medical inpatients. The 2018 American Society of Hematology clinical practice guideline on prophylaxis for hospitalized and nonhospitalized medical patients conditionally recommends chemoprophylaxis for non-critically ill medical inpatients, leaving much to the discretion of the treating physician. Here, 2 experts, a hematologist and a hospitalist, reflect on the care of a woman hospitalized with a rheumatologic disorder. They consider the risks and benefits of chemoprophylaxis, discuss VTE risk stratification, and recommend which patients should receive chemoprophylaxis and with which agents.
4115. Red and Processed Meat Consumption and Risk for All-Cause Mortality and Cardiometabolic Outcomes.
作者: Dena Zeraatkar.;Gordon H Guyatt.;Pablo Alonso-Coello.;Malgorzata M Bala.;Montserrat Rabassa.;Mi Ah Han.;Robin W M Vernooij.;Claudia Valli.;Regina El Dib.;Bradley C Johnston.
来源: Ann Intern Med. 2020年172卷7期511-512页 4120. Relationship of a Claims-Based Frailty Index to Annualized Medicare Costs: A Cohort Study.
Medicare uses the Centers for Medicare & Medicaid Services Hierarchical Condition Category (CMS-HCC) model to predict patients' annualized Medicare costs in value-based payment programs. The CMS-HCC model does not include measures of frailty, and prior research shows that it systematically underpredicts costs for frail Medicare beneficiaries.
|